• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook

    11/6/23 12:14:57 PM ET
    $BNTX
    $BVH
    $CREV
    $DISH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance
    Get the next $BNTX alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday

    The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also rose, gaining, 0.09% to 4,362.35.

    Check This Out: Top 5 Health Care Stocks That May Fall Off A Cliff This Month

     

    Leading and Lagging Sectors

     

    Health care shares jumped by 0.5% on Monday.

    In trading on Monday, real estate shares fell by 1.4%.

     

    Top Headline

     

    BioNTech SE (NASDAQ:BNTX) reported better-than-expected earnings for its third quarter on Monday.

    The company posted third-quarter revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago. Analysts estimated $1.06 billion in sales. The company reported an EPS of €0.67 (around $0.73, beating the consensus of $0.62), a steep decline from €6.98 a year ago.

    BioNTech lowers its FY23 Covid-19 vaccine revenue guidance to around €4 billion, down from prior guidance of approximately €5 billion.

     

    Equities Trading UP

     

    Carbon Revolution Public Limited (NASDAQ:CREV) shares shot up 429% to $155.29 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.

    Shares of Bluegreen Vacations Holding Corporation (NYSE:BVH) got a boost, shooting 106% to $73.04 after the company announced it would be acquired by Hilton Grand Vacations at $75 per share.

    Verb Technology Company, Inc. (NASDAQ:VERB) shares were also up, gaining 31% to $0.3368 amid the company announcing new technology integrations for its MARKET.live platform.

     

    Equities Trading DOWN

     

    MoonLake Immunotherapeutics (NASDAQ:MLTX) shares dropped 23% to $39.46 after the company announced results of its phase 2 study treating active Psoriatic Arthritis.

    Shares of DISH Network Corporation (NASDAQ:DISH) were down 20% to $4.3842 after the company reported third-quarter results. On Nov. 3, 2023, W. Erik Carlson notified DISH that he intends to resign as the CEO effective Nov. 12, 2023.

    EchoStar Corporation (NASDAQ:SATS) was down, falling 19% to $12.46 after the company reported worse-than-expected third-quarter sales.

    Also Check This Out: Bitcoin Falls Below $35,000; Neo, MultiversX Among Top Losers

     

    Commodities

     

    In commodity news, oil traded up 1.7% to $81.88 while gold traded down 0.4% at $1,991.30.

    Silver traded down 0.5% to $23.18 on Monday while copper rose 0.7% to $3.7085.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.26%, London’s FTSE 100 rose 0.04% while Spain’s IBEX 35 Index fell 0.68% The German DAX fell 0.51% French CAC 40 fell 0.57%, while Italy’s FTSE MIB Index fell 0.41%.

    Factory orders in Germany increased 0.2% month-over-month in September compared to a revised 1.9% increase in August. The HCOB Spain Composite PMI edged lower to 50 in October from 50.1 in the earlier month.

     

    Asia Pacific Markets

     

    Asian markets closed higher on Monday, with Japan’s Nikkei 225 gaining 2.37%, Hong Kong’s Hang Seng Index gaining 1.71% and China’s Shanghai Composite Index gaining 0.91%. India’s S&P BSE Sensex, meanwhile, rose around 0.7%.

    The au Jibun Bank Japan services PMI fell to 51.6 in October versus a final reading of 53.8 in September, while composite PMI slipped to 50.5 from a final level of 52.1 in September.

     

    Economics

     

    There were no major US economic releases Monday.

    Now Read This: These 3 Defensive Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts

    Get the next $BNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTX
    $BVH
    $CREV
    $DISH

    CompanyDatePrice TargetRatingAnalyst
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    MoonLake Immunotherapeutics
    $MLTX
    1/15/2026$10.00Neutral → Sell
    Goldman
    MoonLake Immunotherapeutics
    $MLTX
    1/9/2026$24.00Neutral → Buy
    BTIG Research
    EchoStar Corporation
    $SATS
    12/10/2025$110.00Equal-Weight → Overweight
    Morgan Stanley
    MoonLake Immunotherapeutics
    $MLTX
    11/3/2025$30.00Neutral → Buy
    H.C. Wainwright
    MoonLake Immunotherapeutics
    $MLTX
    10/2/2025Buy → Neutral
    H.C. Wainwright
    MoonLake Immunotherapeutics
    $MLTX
    10/1/2025$7.00Buy → Neutral
    Goldman
    More analyst ratings

    $BNTX
    $BVH
    $CREV
    $DISH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Brokaw George R bought $68,070 worth of shares (1,000 units at $68.07), increasing direct ownership by 57% to 2,754 units (SEC Form 4)

    4 - EchoStar CORP (0001415404) (Issuer)

    11/20/25 4:40:47 PM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    Chief Financial Officer Bodenstedt Matthias bought $98,808 worth of Class A ordinary shares (10,870 units at $9.09), increasing direct ownership by 2% to 627,536 units (SEC Form 4)

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    10/9/25 9:01:51 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHAIRMAN Ergen Charles W bought $43,499,994 worth of shares (1,551,355 units at $28.04) (SEC Form 4)

    4 - EchoStar CORP (0001415404) (Issuer)

    11/14/24 5:15:44 PM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    $BNTX
    $BVH
    $CREV
    $DISH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gray Media Forces Blackout of 226 Local Channels, Disrupting DISH TV Customers Nationwide

    ENGLEWOOD, Colo., March 10, 2026 /PRNewswire/ -- Following Gray Media's decision to black out its local stations from the DISH TV lineup, 226 channels in 113 markets are currently unavailable to DISH customers. Gray Media chose to disconnect these stations—which provide critical local news, sports, and weather—after DISH refused to accept unreasonable rate increases that would have raised monthly bills for consumers. Why Are Channels Missing?Gray Media is utilizing its market dominance to demand "retransmission consent" fee hikes that are disconnected from the reality of declini

    3/10/26 6:55:00 PM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

    BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company to research and develop next-generation mRNA innovations; management transition by end of 2026Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to the new company in exchange for a minority stakeSigning of binding agreements expected by end of H1/2026 Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX,

    3/10/26 6:33:07 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $BVH
    $CREV
    $DISH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioNTech upgraded by Goldman with a new price target

    Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $142.00

    1/16/26 8:19:35 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    MoonLake Immunotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded MoonLake Immunotherapeutics from Neutral to Sell and set a new price target of $10.00

    1/15/26 8:33:55 AM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $BVH
    $CREV
    $DISH
    SEC Filings

    View All

    SEC Form 20-F filed by BioNTech SE

    20-F - BioNTech SE (0001776985) (Filer)

    3/10/26 6:55:57 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    3/10/26 6:53:33 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by BioNTech SE

    6-K - BioNTech SE (0001776985) (Filer)

    3/10/26 6:34:31 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $BVH
    $CREV
    $DISH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF LEGAL OFFICER Manson Dean sold $2,180,266 worth of shares (19,031 units at $114.56) and exercised 21,631 shares at a strike of $14.04, increasing direct ownership by 108% to 4,998 units (SEC Form 4)

    4 - EchoStar CORP (0001415404) (Issuer)

    3/9/26 7:48:00 PM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    PRES, TECH & COO Swieringa John sold $5,689,228 worth of shares (50,088 units at $113.58) and exercised 35,088 shares at a strike of $16.57, decreasing direct ownership by 6% to 253,535 units (SEC Form 4)

    4 - EchoStar CORP (0001415404) (Issuer)

    3/6/26 7:11:26 PM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    SEC Form 4 filed by Chief Scientific Officer Reich Kristian

    4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

    1/9/26 4:01:03 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $BVH
    $CREV
    $DISH
    Financials

    Live finance-specific insights

    View All

    BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion2, net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.314) (adjusted3 diluted loss per share of €0.48 ($0.554)) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5Expect 202

    3/10/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EchoStar Announces Financial Results for the Three and Twelve Months Ended December 31, 2025

    ENGLEWOOD, Colo., March 2, 2026 /PRNewswire/ -- EchoStar Corporation (NASDAQ:SATS) reported 2025 total revenue of $15.00 billion, compared to $15.83 billion in 2024. Net loss attributable to EchoStar in 2025 totaled $14.50 billion, compared to $119.55 million in 2024. The net loss in 2025 was primarily attributable to non-cash asset impairments and other expenses totaling approximately $17.63 billion. The net loss in 2024 was positively impacted by a noncash gain totaling approximately $689 million related to our debt exchange offer and the resulting debt extinguishment. Excludi

    3/2/26 6:30:00 AM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

    MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will

    2/24/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $BVH
    $CREV
    $DISH
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $BVH
    $CREV
    $DISH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verb Technology Company Inc.

    SC 13G/A - Verb Technology Company, Inc. (0001566610) (Subject)

    11/15/24 8:24:57 PM ET
    $VERB
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by EchoStar Corporation

    SC 13D/A - EchoStar CORP (0001415404) (Subject)

    11/14/24 4:15:27 PM ET
    $SATS
    Telecommunications Equipment
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care